Michael E Abram

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 11

Top Venues

Nature medicine

Nature communications

Microbiology spectrum

Journal of clinical microbiology

AstraZeneca

University of Pittsburgh (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

AstraZeneca Dec 10 2018

United States

Principal Scientist :: Respiratory & Immunology

Gilead Sciences Dec 01 2010 - Dec 09 2018

United States

Research Scientist :: Clinical Virology

Education History

University of Pittsburgh

United States

PHD :: Molecular Virology and Microbiology

Publications

Bahar Ahani, Kevin M Tuffy, Anastasia A Aksyuk, Deidre Wilkins, Michael E Abram, Ron Dagan, Joseph B Domachowske, Johnathan D Guest, Hong Ji, Anna Kushnir, Amanda Leach, Shabir Ahmed Madhi, Vaishali S Mankad, Eric A F Simões, Benjamin C Sparklin, Scott D Speer, Ann Marie Stanley, David E Tabor, Ulrika Wählby Hamrén, Elizabeth J Kelly, Tonya Villafana
Author Correction: Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials. Nature communications 15 (1) (2024)
Bahar Ahani, Kevin M Tuffy, Anastasia A Aksyuk, Deidre Wilkins, Michael E Abram, Ron Dagan, Joseph B Domachowske, Johnathan D Guest, Hong Ji, Anna Kushnir, Amanda Leach, Shabir Ahmed Madhi, Vaishali S Mankad, Eric A F Simões, Benjamin C Sparklin, Scott D Speer, Ann Marie Stanley, David E Tabor, Ulrika Wählby Hamrén, Elizabeth J Kelly, Tonya Villafana
Author Correction: Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials. Nature communications 15 (1) (2024)
Deidre Wilkins, Yuan Yuan, Yue Chang, Anastasia A Aksyuk, Beatriz Seoane Núñez, Ulrika Wählby-Hamrén, Tianhui Zhang, Michael E Abram, Amanda Leach, Tonya Villafana, Mark T Esser
Author Correction: Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants. Nature medicine (2024)
Deidre Wilkins, Yuan Yuan, Yue Chang, Anastasia A Aksyuk, Beatriz Seoane Núñez, Ulrika Wählby-Hamrén, Tianhui Zhang, Michael E Abram, Amanda Leach, Tonya Villafana, Mark T Esser
Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants. Nature medicine (2023)
Deidre Wilkins, Yuan Yuan, Yue Chang, Anastasia A Aksyuk, Beatriz Seoane Núñez, Ulrika Wählby-Hamrén, Tianhui Zhang, Michael E Abram, Amanda Leach, Tonya Villafana, Mark T Esser
Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants. Nature medicine (2023)
Bahar Ahani, Kevin M Tuffy, Anastasia A Aksyuk, Deidre Wilkins, Michael E Abram, Ron Dagan, Joseph B Domachowske, Johnathan D Guest, Hong Ji, Anna Kushnir, Amanda Leach, Shabir Ahmed Madhi, Vaishali S Mankad, Eric A F Simões, Benjamin C Sparklin, Scott D Speer, Ann Marie Stanley, David E Tabor, Ulrika Wählby Hamrén, Elizabeth J Kelly, Tonya Villafana
Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials. Nature communications 14 (1) (2023)
Deidre Wilkins, Yuan Yuan, Yue Chang, Anastasia A Aksyuk, Beatriz Seoane Núñez, Ulrika Wählby-Hamrén, Tianhui Zhang, Michael E Abram, Amanda Leach, Tonya Villafana, Mark T Esser
Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants. Nature medicine 29 (5) (2023)
Deidre Wilkins, Yuan Yuan, Yue Chang, Anastasia A Aksyuk, Beatriz Seoane Núñez, Ulrika Wählby-Hamrén, Tianhui Zhang, Michael E Abram, Amanda Leach, Tonya Villafana, Mark T Esser
Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants. Nature medicine (2023)
Tyler Brady, Tianhui Zhang, Kevin M Tuffy, Nantaporn Haskins, Qun Du, Jia Lin, Gilad Kaplan, Steven Novick, Tiffany L Roe, Kuishu Ren, Kim Rosenthal, Patrick M McTamney, Michael E Abram, Katie Streicher, Elizabeth J Kelly
Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring. Microbiology spectrum 10 (5) (2022)
Yueh-Ming Loo, Patrick M McTamney, Rosalinda H Arends, Michael E Abram, Anastasia A Aksyuk, Seme Diallo, Daniel J Flores, Elizabeth J Kelly, Kuishu Ren, Richard Roque, Kim Rosenthal, Katie Streicher, Kevin M Tuffy, Nicholas J Bond, Owen Cornwell, Jerome Bouquet, Lily I Cheng, James Dunyak, Yue Huang, Anton I Rosenbaum, Venkatesh Pilla Reddy, Hanne A Elyard, Robert H Carnahan, James E Crowe, Ana I Kuehne, Andrew S Herbert, John M Dye, Helen Bright, Nicole L Kallewaard, Menelas N Pangalos, Mark T Esser
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans. Science translational medicine 14 (635) (2022)
David E Tabor, Fiona Fernandes, Annefleur C Langedijk, Deidre Wilkins, Robert Jan Lebbink, Andrey Tovchigrechko, Alexey Ruzin, Leyla Kragten-Tabatabaie, Hong Jin, Mark T Esser, Louis J Bont, Michael E Abram, null null
Global Molecular Epidemiology of Respiratory Syncytial Virus from the 2017-2018 INFORM-RSV Study. Journal of clinical microbiology 59 (1) (2020)

Michael E Abram.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Michael E Abram